Q1 Net Loss Halved, Cash Position Boosted by $110M Offering, Extending Runway

summarizeSummary

Sutro Biopharma reported a reduced net loss and a strengthened cash position in Q1 2026, driven by a $110 million equity offering and completed restructuring, extending its cash runway for over a year.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $(38.5) million for Q1 2026, a significant improvement from $(76.0) million in Q1 2025. Revenue decreased to $14.5 million from $17.4 million year-over-year.

• Strengthened Cash Position

  Unrestricted cash, cash equivalents, and marketable securities increased to $202.6 million as of March 31, 2026, up from $134.6 million at December 31, 2025.

• Extended Cash Runway

  Management believes existing capital resources will fund operations for at least 12 months following the filing date (March 31, 2026).

• $110 Million Underwritten Offering

  Completed an underwritten public offering in February 2026, issuing 7,868,383 shares at $13.98 per share, generating approximately $110.0 million in gross proceeds. This offering was previously disclosed in the 10-K and 424B3 filings.

auto_awesomeAnalysis

Sutro Biopharma reported a significant reduction in its net loss for Q1 2026, nearly halving it compared to the prior year. The company substantially increased its cash reserves to over $200 million through a $110 million underwritten offering, which is crucial for a clinical-stage biotech. This capital raise, while dilutive, extends the company's operational runway for at least 12 months and follows the completion of a major restructuring effort aimed at cost reduction. The company also recognized a $10 million milestone payment from its Astellas collaboration.